Company / Return on Equity (ROE)
Sarepta Therapeutics Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-62.5%
FY2025
5-year range
-72.7% / 15.4%
FY2021-FY2025
Trend
-506.2%
vs FY2024
Sector context
#151 of 190
Health Care
What the data says
Sarepta Therapeutics reports negative total equity of -62.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-62.5% in FY2025 with a 5-year CAGR of -27.5%.
Remained stable around -62.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +10.2pp
- 5-Year Change
- -27.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 190This company -62.5% Sector average -50.3%
▼
-24.3% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 506.2% year-over-year.
- Currently 12.2pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -62.5% | -506.2% |
| FY2024 | 15.4% | +124.7% |
| FY2023 | -62.4% | +14.3% |
| FY2022 | -72.7% | -61.2% |
| FY2021 | -45.1% | -28.7% |
| FY2020 | -35.1% | -446.1% |
| FY2019 | -6.4% | +81.7% |
| FY2018 | -35.1% | -446.1% |
| FY2017 | -6.4% | +91.9% |
| FY2016 | -79.4% | +31.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026